Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Acute Bacterial Skin and Skin Structure Infections.
Saved in:
| Title: | Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Acute Bacterial Skin and Skin Structure Infections. |
|---|---|
| Authors: | Howard-Anderson J; Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA., Hamasaki T; The Biostatistics Center and Department of Biostatics and Bioinformatics, Milken Institute School of Public Health, George Washington University, Washington, D.C., USA., Ge L; The Biostatistics Center and Department of Biostatics and Bioinformatics, Milken Institute School of Public Health, George Washington University, Washington, D.C., USA., Collyar D; Patient Advocates in Research, Danville, California, USA., Cosgrove SE; Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Doernberg SB; Division of Infectious Diseases, Department of Medicine, University of California School of Medicine, SanFrancisco, California, USA., Geres H; Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA., Gopinath R; Center for Drug Evaluation and Research, United States Food and Drug Administration, Washington, D.C., USA., Holland TL; Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.; Division of Infectious Diseases, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA., King HA; Division of Internal Medicine, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.; Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina, USA.; Center of Innovation to Accelerate Discovery and Practice Transformation (ADAPT), Durham Veterans Affairs Health Care System, Durham, North Carolina, USA., Nambiar S; Johnson & Johnson, Raritan, New Jersey, USA., Rubin D; Center for Drug Evaluation and Research, United States Food and Drug Administration, Washington, D.C., USA., Chambers HF; Division of Infectious Diseases, Department of Medicine, University of California School of Medicine, SanFrancisco, California, USA., Fowler VG; Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.; Division of Infectious Diseases, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA., Evans SR; The Biostatistics Center and Department of Biostatics and Bioinformatics, Milken Institute School of Public Health, George Washington University, Washington, D.C., USA., Boucher HW; Tufts University School of Medicine and Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, Massachusetts, USA. |
| Source: | Open forum infectious diseases [Open Forum Infect Dis] 2026 Jun 22; Vol. 13 (6), pp. ofag320. Date of Electronic Publication: 2026 Jun 22 (Print Publication: 2026). |
| Publication Type: | Clinical Trial; Journal Article |
| Journal Info: | Publisher: Published by Oxford University Press on behalf of the Infectious Diseases Society of America Country of Publication: United States NLM ID: 101637045 Publication Model: eCollection Cited Medium: Print ISSN: 2328-8957 (Print) Linking ISSN: 23288957 NLM ISO Abbreviation: Open Forum Infect Dis Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2328-8957 |
|---|---|
| DOI: | 10.1093/ofid/ofag320 |
